ArticleScientific reports2025
Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2- advanced or metastatic breast cancer in China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HRTranslational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
- Clinical Efficacy and Security Analysis of CDK4/6 Inhibitors Combined with ET in Patients with HRCancer management and research · 2026Article
- Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China.Frontiers in pharmacology · 2026Article
- Review
- Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial.Frontiers in pharmacology · 2025Article
- CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies for treatment.Frontiers in pharmacology · 2025Review
- Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hormone receptor HR-positive/HER2-negative (HR+/HER2-) breast cancer is the most common subtype in China, representing 60-70% of cases, with a rising incidence due to aging demographics and lifestyle changes. CDK4/6 inhibitors such as palbociclib, ribociclib and abemaciclib have been proven effective in treating HR+/HER2 - advanced or metastatic breast cancer (ABC/MBC), though they may increase healthcare costs. This study aims to compare the efficacy, safety and cost-effectiveness of CDK4/6 inhibitors for the second-line treatment of HR+/HER2 - ABC/MBC from the Chinese healthcare perspective. A cohort-based partitioned survival model was utilized, drawing on the survival data published from PALOMA-3, MONALEESA-3 and MONARCH-2 trials. Costs, and quality-adjusted life years (QALYs) were used to calculate the incremental cost-effectiveness ratio (ICER) over a 15-year time horizon. Deterministic and probabilistic sensitivity analyses were performed to assess the robustness of the model results. In the base-case analysis, the model estimated health benefits to be 2.10 QALYs for palbociclib plus fulvestrant (PAL + FUL), 2.55 QALYs for ribociclib plus fulvestrant (RIB + FUL), and 2.60 QALYs for abemaciclib plus fulvestrant (ABE + FUL), with corresponding costs of $34,423, $41,119, and $48,019. Compared with PAL + FUL, the ICERs were $27,161 per QALY for ABE + FUL and $15,073 per QALY for RIB + FUL. The robustness of these findings was confirmed through uncertainty analyses. Among the three strategies, the most cost-effective probabilities of PAL + FUL, RIB + FUL and ABE + FUL were 0%, 99.8%, and 0.2% under the willingness-to-pay (WTP) threshold of 3 times per-capita gross domestic product ($37,738) in China. This study indicated that both RIB + FUL and ABE + FUL are cost-effective at the WTP threshold compared with PAL + FUL. Notably, RIB + FUL offers the greatest cost-effective advantage for the second-line treatment of HR+/HER2 - ABC/MBC among these three CDK4/6 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.